Skip to main content
Premium Trial:

Request an Annual Quote

Yeda Research and Development Company, Bristol-Myers Squibb, Andrew Makarovskiy, Stanford University, and Cadus Technologies Awarded US Patents

Premium
Yeda Research and Development Company of Rehovot, Israel, has been awarded US Patent 7,225,172, “Method and apparatus for multivariable analysis of biological measurements.”
 
The inventor listed on the patent is Zvi Kam.
 
As stated in the abstract, the patent describes a “method and apparatus for analyzing multivariable data sets.” A general computerized platform is provided for evaluating the relationship between large numbers of measurements of sets of variables that characterize components of complex states of a system under induced stimulation or controlled conditions. According to the abstract, “Applications in biology include analysis of measurements characterizing responses of molecular components in cells under changes induced by stimuli [for example, drugs, growth factors, hormones, mutations, or forced expression of a proteins], and identification of complex cellular states [for example, proliferation, differentiation, transformation, starvation, necrosis, apoptosis, and the time dependencies of the above effects].”
 

 
Bristol-Myers Squibb has been awarded US Patent 7,223,834, “Assays and peptide substrate for determining aggrecan degrading metallo protease activity.”
 
Inventors listed on the abstract are Jeffrey Miller, Elizabeth Arner, Robert Copeland, Gary Davis, Ruiqin Liu, Michael Pratta, and Micky Tortorella,
 
The patent protects assays for determining the presence or absence of proteins that exhibit aggrecanase activity. and also “relates to peptides that act as substrates for ADMPs, their use in various assays to determine the presence or absence of ADMP activity, and their use as inhibitors of ADMP activity,” according to the abstract.
 

 
Andrew Makarovskiy has been awarded US Patent 7,223,549, “Compositions for the identification and isolation of stem cells.”
 
The invention describes monoclonal antibodies that selectively bind to ectodermally and endodermally derived stem cells, and methods for diagnosing a neoplasm in a subject by contacting a tissue sample from the subject with the antibodies. The patent also discloses “methods for isolating such stem cells from a heterogeneous cell population by contacting the population with antibodies which selectively bind to stem cells,” according to the abstract.
 

 
The Stanford University Board of Trustees has been awarded US Patent 7,223,537, “Detection of molecular interactions by reporter subunit complementation.”
 
Inventors listed on the patent are Helen Blau, Fabio Rossi, and William Mohler.
 
The patent protects methods for detecting molecular interactions, particularly protein-protein interactions, in living cells or in vitro. “Detection of molecular interactions in living cells is not limited to the nuclear compartment, but can be accomplished in the cytoplasm, cell surface, organelles, or between these entities,” according to the abstract. In one embodiment, the method uses compositions comprising fusion proteins between the molecules of interest and two or more inactive, weakly complementing beta-galactosidase mutants. Association between molecules of interest brings the complementing beta-galactosidase mutants into proximity so that complementation occurs and active beta-galactosidase is produced. “Among the uses of the invention are the study of protein-protein interactions, functional genomics, agonist and antagonist screening, and drug discovery,” the abstract states.
 

 
Cadus Technologies of New York City has been awarded US Patent 7,223,533, “Cell surface proteins and use thereof as indicators of activation of cellular signal transduction pathways.”
 
Inventors listed on the patent are Kirill Ostanin, Mary Cismowski, and Lauren Silverman.
 
The invention makes available “a rapid, reproducible, robust assay system for screening and identifying pharmaceutically effective compounds that specifically interact with and modulate the activity of a cellular protein, for example, a receptor or ion channel,” according to the patent abstract. The assay enables rapid screening of large numbers of compounds to identify those which act as an agonist or antagonist to the bioactivity of the cellular protein. In the system, the cell is treated with a compound, and functional interaction of this compound with a cellular receptor yields a signal that can be measured. The assays include methods of identifying compounds that modulate, for example, heterologous receptors coupled to the pheromone response pathway in yeast. “The subject assays are particularly amenable to the identification of specific agonists and antagonists of G protein-coupled receptors,” according to the abstract.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.